Please wait while the formulary information is being retrieved.
PROMETRIUM (progesterone, micronized)
- absence of menstrual periods in woman who has had them
- prevention of abnormal growth in cells of uterine lining
100 mg capsule
- 2 capsules (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
200 mg capsule
- 1 capsule (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
100 mg capsule
- 2 capsules (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
200 mg capsule
- 1 capsule (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
micronized 100 mg capsule
- 2 capsules (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
micronized 200 mg capsule
- 1 capsule (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
Endometrial hyperplasia prevention
- 1 capsule (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
- 2 capsules (200 mg) by oral route once daily in the evening for 12 days sequentially per 28 day cycle
Secondary amenorrhea
- 4 capsules (400 mg) by oral route once daily in the evening for 10 days
- 2 capsules (400 mg) by oral route once daily in the evening for 10 days
- None
Contraindicated
- None
Severe
Moderate
- None
- Carcinoma of breast
- Disease of liver
- Neoplasm of liver
- Porphyria
Contraindicated
- Acute myocardial infarction
- Bed-ridden
- Cerebrovascular accident
- Coronary artery disease
- Deep venous thrombosis
- Migraine
- Obesity
- Predisposition to thrombosis
- Pulmonary thromboembolism
- Retinal thrombosis
- Thromboembolic disorder
- Thrombophlebitis
- Tobacco smoker
Severe
Moderate
- Depression
- Diabetes mellitus
- Edema
- Hyperlipidemia
- Hypertension
PROMETRIUM (progesterone, micronized)
- absence of menstrual periods in woman who has had them
- prevention of abnormal growth in cells of uterine lining
- Abdominal distension
- Abnormal vaginal bleeding
- Irregular menstrual periods
- Back pain
- Edema
- Fatigue
- Headache disorder
- Myalgia
- Vaginitis
- Weight loss
More Frequent
Severe
Less Severe
- Endometrial hyperplasia
- Dizziness
- Dyspepsia
- Ectropion of cervix
- Hypertonia
- Vaginal discharge
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Depression
- Ectopic pregnancy
- Erythema multiforme
- Erythema nodosum
- Galactorrhea not associated with childbirth
- Hypersensitivity drug reaction
- Hypertension
- Malignant neoplasm of the ovary
- Menorrhagia
- Obstructive hyperbilirubinemia
- Optic neuritis
- Ovarian cyst
- Pancreatitis
- Pruritus of skin
- Pulmonary thromboembolism
- Retinal thrombosis
- Thromboembolic disorder
- Thrombophlebitis
Less Severe
- Acne vulgaris
- Alopecia
- Amenorrhea
- Body fluid retention
- Cervical discharge
- Chloasma
- Constipation
- Drowsy
- Fever
- Fibrocystic breast disease
- Hirsutism
- Hyperglycemia
- Insomnia
- Irritability
- Mastalgia
- Migraine
- Nausea
- Nervousness
- Pain in extremities
- Skin rash
- Urticaria
- Weight gain
Contraindicated
None
Severe Precaution
Progesterones (Select)
Not indicated in children.
- 1 Day – 12 Years
- Not indicated in children.
Management or Monitoring Precaution
None
Progesterone
- Severity Level:
B
- Additional Notes: Insufficient human data; animal data do not suggest dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Progesterone
Data suggest low amount excreted with no adverse effects on infants
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Data suggest low amount excreted with no adverse effects on infants |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Progesterone is sometimes used with another medication (a type of estrogen) as combination hormone replacement therapy (HRT) in women after menopause. Combination HRT can rarely cause very serious side effects such as heart disease (e.g., heart attacks), stroke, serious blood clots (e.g., in the lungs and legs), dementia, and breast cancer. Some of these risks appear to depend on the length of treatment and other factors.<br /><br />Therefore, combination HRT should be used for the shortest possible length of time at the lowest effective dose so you can obtain the benefits and minimize the chance of serious side effects from long-term treatment. Combination HRT should not be used to prevent heart disease or dementia. Discuss the risks and benefits of treatment and your personal health history with your doctor.<br /><br /> If you take combination HRT, check with your doctor regularly (e.g., every 3-6 months) to see if you still need to take it. If you use this medication for an extended period, you should have a complete physical exam at regular intervals (e.g., once a year) or as directed by your doctor. See Notes section.
| Secondary amenorrhea | |
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
| 0-9 | A-Z |
|---|---|
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
Formulary Reference Tool